Seeing through the patient’s Eyes: Exploring quality of life in glaucoma patients
Journal of Advanced Pharmaceutical Technology & Research · 2026-04 · 17 (2) · 141-147
DOI: 10.4103/japtr.japtr_304_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Pharmaceutical Technology & Research, online erschienen am 09.05.2026. Verfasst von Nour Aymn Ahmad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Glaucoma remains the predominant cause of irreversible blindness and has a profound multidimensional impact on every patient’s life. Assessment of vision-related quality of life (VR-QOL) is paramount for comprehensive glaucoma management. To evaluate VR-QOL among patients with glaucoma at a secondary care hospital in the United Arab Emirates. This cross-sectional study was undertaken in the ophthalmology outpatient clinic between July 2021 and February 2022. Individuals were recruited using stratified random sampling, and controls were frequency-matched by age and gender. VR-QOL was measured using the validated NEI-VFQ-25 questionnaire. Descriptive statistics, Mann–Whitney U -tests, Spearman correlation, and to analyze predictors associated with VR-QOL, multiple linear regression were used. The study was completed by 130 individuals with glaucoma and 130 control subjects. The average composite NEI-VFQ-25 score for glaucoma patients was lower than control groups. VR-QOL was strongly related to disease severity, age, number of medications, and occupation status ( P < 0.05). Significant difference was observed across multiple functional domains in patient with glaucoma compared to controls ( P < 0.05). Glaucoma substantially affects VR-QOL, particularly in advanced stages of the disease. Elderly, duration of the illness, and long-term treatment greatly influence diminishing patient well-being. These findings underscore the need for ongoing monitoring, patient-centered engagement, and most importantly, the early detection of glaucoma to preserve vision.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE.
- Department of Pharmacy Practice, College of Pharmacy, Dubai Medical University, UAE.
- Department of Ophthalmology, Clinical Scienecs Division, NOSM University, Thunder Bay, Ontario, Canada.
Zitieren
APA
Ahmad, N. A., Sridhar, S. B., Shareef, J., & Kamath, A. (2026). Seeing through the patient’s Eyes: Exploring quality of life in glaucoma patients. Journal of Advanced Pharmaceutical Technology & Research, 17(2), 141-147. https://doi.org/10.4103/japtr.japtr_304_25
Vancouver
Ahmad NA, Sridhar SB, Shareef J, Kamath A. Seeing through the patient’s Eyes: Exploring quality of life in glaucoma patients. Journal of Advanced Pharmaceutical Technology & Research. 2026;17(2):141-147. doi:10.4103/japtr.japtr_304_25
BibTeX
@article{Ahmad2026,
author = {Ahmad, Nour Aymn and Sridhar, Sathvik Belagodu and Shareef, Javedh and Kamath, Ajay},
title = {Seeing through the patient’s Eyes: Exploring quality of life in glaucoma patients},
journal = {Journal of Advanced Pharmaceutical Technology & Research},
year = {2026},
volume = {17},
number = {2},
pages = {141--147},
doi = {10.4103/japtr.japtr_304_25}
}
EUVIMED